JUN 22, 2020 3:36 PM PDT

MDMA Has Long-Term Benefits Against PTSD

WRITTEN BY: Annie Lennon

Researchers have shown that MDMA-assisted psychotherapy has therapeutic effects that last over a year in treating post-traumatic stress disorder (PTSD). 

The new paper explores the long-term outcomes for people a year after completing MDMA psychotherapies. Comprising follow-up data from six previous trials, all in all, the researchers gathered data on around 100 patients. 

Participants in each trial underwent two to three therapy sessions with active doses of MDMA (75-125mg) alongside additional regular psychotherapy sessions. Their PTSD symptoms were measured using the Clinician-Administered PTSD Scale for DSM IV at baseline either one or two months following their last MDMA session, and then at least 12 months after that. Each participant also filled in a long-term follow-up survey. 

At the first follow-up, the researchers noted that 56% of the cohort no longer met the clinical criteria for PTSD. However, after the second follow-up, they found that participants tended to continue to improve over the year. This meant that 12 months on from the MDMA-sessions, 67% of the cohort no longer met the criteria for PTSD. 

The researchers also noted that after treatment, patients tended to have fewer suicidal thoughts and general PTSD symptoms. Their data also suggested that MDMA therapy does not lead to MDMA abuse nor any other substance abuse. 

"These long-term follow-up findings show that once people with PTSD learn that they can productively process traumatic memories instead of suppressing them, they can continue to heal themselves even after they have stopped receiving MDMA-assisted psychotherapy," says Rick Doblin, one of the authors of the study. 

Following the success of these Phase II trials, MDMA-assisted therapy is now in Phase III human trials for severe, treatment-resistant PTSD, with US Food and Drug Administration (FDA) approval expected in 2022. 

Meanwhile, due to the effectiveness of the treatment, earlier this year, the FDA approved it for Expanded Access, allowing select patients to access the procedure before it has full-market approval. 


Sources: New Atlas, Springer,

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
NOV 25, 2020
Drug Discovery & Development
Improving Drug Dissolution
NOV 25, 2020
Improving Drug Dissolution
When you take your medicine, it travels through the bloodstream and releases its effects. When the drug dissolves too fa ...
DEC 02, 2020
Immunology
A Shingles Vaccine for Cancer Patients
DEC 02, 2020
A Shingles Vaccine for Cancer Patients
Receiving a vaccine (usually in the form of an inactivated pathogen) triggers an immune response without the symptoms of ...
DEC 03, 2020
Drug Discovery & Development
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
DEC 03, 2020
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
Last month, Oregon became the first state in the US to legalize psilocybin mushrooms as a therapeutic treatment. Now, th ...
DEC 15, 2020
Cannabis Sciences
Could Cannabis Help in the Opioid Crisis?
DEC 15, 2020
Could Cannabis Help in the Opioid Crisis?
While cannabis is increasingly available for medicinal use, doctors largely remain unable to prescribe it to their patie ...
JAN 09, 2021
Drug Discovery & Development
Anticoagulant Drugs Prevent Cancer Spreading to Brain
JAN 09, 2021
Anticoagulant Drugs Prevent Cancer Spreading to Brain
Researchers from the Heidelberg University in Germany have found that anticoagulant drugs that inhibit thrombin (an enzy ...
Loading Comments...